-
1
-
-
33745325861
-
Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: Results from the Veterans Administration Genetic Epidemiology Study
-
Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 55: 1430-1435, 2006.
-
(2006)
Diabetes
, vol.55
, pp. 1430-1435
-
-
Abdul-Ghani, M.A.1
Jenkinson, C.P.2
Richardson, D.K.3
Tripathy, D.4
DeFronzo, R.A.5
-
2
-
-
0141446274
-
Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans
-
Ahren B, Holst JJ, Mari A. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. Diabetes Care 26: 2860-2864, 2003.
-
(2003)
Diabetes Care
, vol.26
, pp. 2860-2864
-
-
Ahren, B.1
Holst, J.J.2
Mari, A.3
-
3
-
-
33947169057
-
-
Ahren B, Taborsky GJ. Beta-cell function and insulin secretion. In: Ellenberg Rifkins Diabetes Mellitus, edited by Porte D, Sherwin RS, and Baron A. New York: McGraw Hill, 2003, p. 43-65.
-
Ahren B, Taborsky GJ. Beta-cell function and insulin secretion. In: Ellenberg Rifkins Diabetes Mellitus, edited by Porte D, Sherwin RS, and Baron A. New York: McGraw Hill, 2003, p. 43-65.
-
-
-
-
4
-
-
77049274176
-
Measurement of size and turnover rate of body glucose pool by the isotope dilution method
-
Altszuler N, De Bodo RC, Steele R, Wall JS. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187: 15-24, 1956.
-
(1956)
Am J Physiol
, vol.187
, pp. 15-24
-
-
Altszuler, N.1
De Bodo, R.C.2
Steele, R.3
Wall, J.S.4
-
5
-
-
2942515930
-
Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients
-
Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 28: 783-789, 2004.
-
(2004)
Int J Obes Relat Metab Disord
, vol.28
, pp. 783-789
-
-
Bajaj, M.1
Suraamornkul, S.2
Hardies, L.J.3
Pratipanawatr, T.4
DeFronzo, R.A.5
-
6
-
-
0842313004
-
Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients
-
Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 89: 200-206, 2004.
-
(2004)
J Clin Endocrinol Metab
, vol.89
, pp. 200-206
-
-
Bajaj, M.1
Suraamornkul, S.2
Piper, P.3
Hardies, L.J.4
Glass, L.5
Cersosimo, E.6
Pratipanawatr, T.7
Miyazaki, Y.8
DeFronzo, R.A.9
-
7
-
-
1442352339
-
Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: Peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach
-
Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89: 463-478, 2004.
-
(2004)
J Clin Endocrinol Metab
, vol.89
, pp. 463-478
-
-
Bays, H.1
Mandarino, L.2
DeFronzo, R.A.3
-
8
-
-
0036183630
-
The mechanisms of action of PPARs
-
Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 53: 409-435, 2002.
-
(2002)
Annu Rev Med
, vol.53
, pp. 409-435
-
-
Berger, J.1
Moller, D.E.2
-
9
-
-
0036615275
-
The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes
-
Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 32, Suppl 3: 35-45, 2002.
-
(2002)
Eur J Clin Invest
, vol.32
, Issue.SUPPL. 3
, pp. 35-45
-
-
Bergman, R.N.1
Finegood, D.T.2
Kahn, S.E.3
-
10
-
-
0036724346
-
Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women
-
Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51: 2796-2803, 2002.
-
(2002)
Diabetes
, vol.51
, pp. 2796-2803
-
-
Buchanan, T.A.1
Xiang, A.H.2
Peters, R.K.3
Kjos, S.L.4
Marroquin, A.5
Goico, J.6
Ochoa, C.7
Tan, S.8
Berkowitz, K.9
Hodis, H.N.10
Azen, S.P.11
-
11
-
-
0032999260
-
Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation
-
Carpentier A, Mittelman SD, Lamarche B, Bergman RN, Giacca A, Lewis GF. Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am J Physiol Endocrinol Metab 276: E1055-E1066, 1999.
-
(1999)
Am J Physiol Endocrinol Metab
, vol.276
-
-
Carpentier, A.1
Mittelman, S.D.2
Lamarche, B.3
Bergman, R.N.4
Giacca, A.5
Lewis, G.F.6
-
12
-
-
0030762562
-
Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance
-
Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 100: 530-537, 1997.
-
(1997)
J Clin Invest
, vol.100
, pp. 530-537
-
-
Cavaghan, M.K.1
Ehrmann, D.A.2
Byrne, M.M.3
Polonsky, K.S.4
-
13
-
-
0035205594
-
A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus
-
Discussion 1791
-
Chilcott J, Tappenden P, Jones ML, Wight JP. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 23: 1792-1823, Discussion 1791, 2001.
-
(2001)
Clin Ther
, vol.23
, pp. 1792-1823
-
-
Chilcott, J.1
Tappenden, P.2
Jones, M.L.3
Wight, J.P.4
-
14
-
-
0030724591
-
Pathogenesis of type 2 diabetes: Metabolic and molecular implications for identifying diabetes genes
-
DeFronzo R. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5: 177-269, 1997.
-
(1997)
Diabetes Rev
, vol.5
, pp. 177-269
-
-
DeFronzo, R.1
-
15
-
-
0024026298
-
Lilly lecture 1987. The triumvirate: Beta-cell, muscle, liver. A collusion responsible for NIDDM
-
DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37: 667-687, 1988.
-
(1988)
Diabetes
, vol.37
, pp. 667-687
-
-
DeFronzo, R.A.1
-
17
-
-
0029126350
-
Reciprocal variations in insulin-stimulated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance
-
Diamond MP, Thornton K, Connolly-Diamond M, Sherwin RS, De-Fronzo RA. Reciprocal variations in insulin-stimulated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance. J Soc Gynecol Investig 2: 708-715, 1995.
-
(1995)
J Soc Gynecol Investig
, vol.2
, pp. 708-715
-
-
Diamond, M.P.1
Thornton, K.2
Connolly-Diamond, M.3
Sherwin, R.S.4
De-Fronzo, R.A.5
-
18
-
-
0346157020
-
Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes
-
Diani AR, Sawada G, Wyse B, Murray FT, Khan M. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab 286: E116-E122, 2004.
-
(2004)
Am J Physiol Endocrinol Metab
, vol.286
-
-
Diani, A.R.1
Sawada, G.2
Wyse, B.3
Murray, F.T.4
Khan, M.5
-
19
-
-
0033811933
-
Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells
-
Dubois M, Pattou F, Kerr-Conte J, Gmyr V, Vandewalle B, Desreumaux P, Auwerx J, Schoonjans K, Lefebvre J. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 43: 1165-1169, 2000.
-
(2000)
Diabetologia
, vol.43
, pp. 1165-1169
-
-
Dubois, M.1
Pattou, F.2
Kerr-Conte, J.3
Gmyr, V.4
Vandewalle, B.5
Desreumaux, P.6
Auwerx, J.7
Schoonjans, K.8
Lefebvre, J.9
-
20
-
-
12244299450
-
beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: A new analysis
-
Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, De-Fronzo RA. beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 90: 493-500, 2005.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 493-500
-
-
Ferrannini, E.1
Gastaldelli, A.2
Miyazaki, Y.3
Matsuda, M.4
Mari, A.5
De-Fronzo, R.A.6
-
21
-
-
0035042679
-
Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death
-
Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, Leonard T, Buckingham RE. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 50: 1021-1029, 2001.
-
(2001)
Diabetes
, vol.50
, pp. 1021-1029
-
-
Finegood, D.T.1
McArthur, M.D.2
Kojwang, D.3
Thomas, M.J.4
Topp, B.G.5
Leonard, T.6
Buckingham, R.E.7
-
22
-
-
21244443895
-
Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity
-
Fukuen S, Iwaki M, Yasui A, Makishima M, Matsuda M, Shimomura I. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J Biol Chem 280: 23653-23659, 2005.
-
(2005)
J Biol Chem
, vol.280
, pp. 23653-23659
-
-
Fukuen, S.1
Iwaki, M.2
Yasui, A.3
Makishima, M.4
Matsuda, M.5
Shimomura, I.6
-
23
-
-
0942279564
-
Beta-cell dysfunction and glucose intolerance: Results from the San Antonio metabolism (SAM) study
-
Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47: 31-39, 2004.
-
(2004)
Diabetologia
, vol.47
, pp. 31-39
-
-
Gastaldelli, A.1
Ferrannini, E.2
Miyazaki, Y.3
Matsuda, M.4
DeFronzo, R.A.5
-
24
-
-
33845424578
-
The effect of pioglitazone on the liver: Role of adiponectin
-
Gastaldelli A, Miyazaki Y, Mahankali A, Berria R, Pettiti M, Buzzigoli E, Ferrannini E, DeFronzo RA. The effect of pioglitazone on the liver: role of adiponectin. Diabetes Care 29: 2275-2281, 2006.
-
(2006)
Diabetes Care
, vol.29
, pp. 2275-2281
-
-
Gastaldelli, A.1
Miyazaki, Y.2
Mahankali, A.3
Berria, R.4
Pettiti, M.5
Buzzigoli, E.6
Ferrannini, E.7
DeFronzo, R.A.8
-
25
-
-
33644824915
-
The effect of rosiglitazone on the liver: Decreased gluconeogenesis in patients with type 2 diabetes
-
Gastaldelli A, Miyazaki Y, Pettiti M, Santini E, Ciociaro D, Defronzo RA, Ferrannini E. The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes. J Clin Endocrinol Metab 91: 806-812, 2006.
-
(2006)
J Clin Endocrinol Metab
, vol.91
, pp. 806-812
-
-
Gastaldelli, A.1
Miyazaki, Y.2
Pettiti, M.3
Santini, E.4
Ciociaro, D.5
Defronzo, R.A.6
Ferrannini, E.7
-
26
-
-
33845284881
-
Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance
-
González-Ortiz M, Hernández-Salazar E, Kam-Ramos AM, Martínez-Abundis E. Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance. Diabetes Res Clin Pract 75: 115-118, 2007.
-
(2007)
Diabetes Res Clin Pract
, vol.75
, pp. 115-118
-
-
González-Ortiz, M.1
Hernández-Salazar, E.2
Kam-Ramos, A.M.3
Martínez-Abundis, E.4
-
27
-
-
0024392514
-
Glucose and free fatty acid metabolism in non-insulin- dependent diabetes mellitus. Evidence for multiple sites of insulin resistance
-
Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo RA. Glucose and free fatty acid metabolism in non-insulin- dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 84: 205-213, 1989.
-
(1989)
J Clin Invest
, vol.84
, pp. 205-213
-
-
Groop, L.C.1
Bonadonna, R.C.2
DelPrato, S.3
Ratheiser, K.4
Zyck, K.5
Ferrannini, E.6
DeFronzo, R.A.7
-
28
-
-
0346027235
-
Muscle-specific Pparg deletion causes insulin resistance
-
Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wilkes J, Evans RM, Olefsky J. Muscle-specific Pparg deletion causes insulin resistance. Nat Med 9: 1491-1497, 2003.
-
(2003)
Nat Med
, vol.9
, pp. 1491-1497
-
-
Hevener, A.L.1
He, W.2
Barak, Y.3
Le, J.4
Bandyopadhyay, G.5
Olson, P.6
Wilkes, J.7
Evans, R.M.8
Olefsky, J.9
-
29
-
-
0033613181
-
Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats
-
Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, Unger RH. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci USA 96: 11513-11518, 1999.
-
(1999)
Proc Natl Acad Sci USA
, vol.96
, pp. 11513-11518
-
-
Higa, M.1
Zhou, Y.T.2
Ravazzola, M.3
Baetens, D.4
Orci, L.5
Unger, R.H.6
-
30
-
-
13444311744
-
Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes
-
Inukai K, Watanabe M, Nakashima Y, Takata N, Isoyama A, Sawa T, Kurihara S, Awata T, Katayama S. Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes. Biochem Biophys Res Commun 328: 484-490, 2005.
-
(2005)
Biochem Biophys Res Commun
, vol.328
, pp. 484-490
-
-
Inukai, K.1
Watanabe, M.2
Nakashima, Y.3
Takata, N.4
Isoyama, A.5
Sawa, T.6
Kurihara, S.7
Awata, T.8
Katayama, S.9
-
31
-
-
12144290529
-
Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress
-
Ishida H, Takizawa M, Ozawa S, Nakamichi Y, Yamaguchi S, Katsuta H, Tanaka T, Maruyama M, Katahira H, Yoshimoto K, Itagaki E, Nagamatsu S. Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: possible protection of beta cells from oxidative stress. Metabolism 53: 488-494, 2004.
-
(2004)
Metabolism
, vol.53
, pp. 488-494
-
-
Ishida, H.1
Takizawa, M.2
Ozawa, S.3
Nakamichi, Y.4
Yamaguchi, S.5
Katsuta, H.6
Tanaka, T.7
Maruyama, M.8
Katahira, H.9
Yoshimoto, K.10
Itagaki, E.11
Nagamatsu, S.12
-
32
-
-
0041883085
-
Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: Evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility
-
Juhl CB, Hollingdal M, Porksen N, Prange A, Lonnqvist F, Schmitz O. Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab 88: 3794-3800, 2003.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 3794-3800
-
-
Juhl, C.B.1
Hollingdal, M.2
Porksen, N.3
Prange, A.4
Lonnqvist, F.5
Schmitz, O.6
-
33
-
-
0034853485
-
Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes
-
Kahn SE. Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86: 4047-4058, 2001.
-
(2001)
J Clin Endocrinol Metab
, vol.86
, pp. 4047-4058
-
-
Kahn, S.E.1
-
34
-
-
4143110082
-
Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes
-
Kashyap SR, Belfort R, Berria R, Suraamornkul S, Pratipranawatr T, Finlayson J, Barrentine A, Bajaj M, Mandarino L, DeFronzo R, Cusi K. Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. Am J Physiol Endocrinol Metab 287: E537-E546, 2004.
-
(2004)
Am J Physiol Endocrinol Metab
, vol.287
-
-
Kashyap, S.R.1
Belfort, R.2
Berria, R.3
Suraamornkul, S.4
Pratipranawatr, T.5
Finlayson, J.6
Barrentine, A.7
Bajaj, M.8
Mandarino, L.9
DeFronzo, R.10
Cusi, K.11
-
35
-
-
1442272497
-
Effects of sustained reduction in plasma FFA concentration on insulin secretion in non-diabetic subjects with a strong family history of T2DM (Abstract)
-
Kashyap SR, Suraamornkul S, Bajaj M, Belfort R, Berria R, Mandarino L, DeFronzo R, Cusi K. Effects of sustained reduction in plasma FFA concentration on insulin secretion in non-diabetic subjects with a strong family history of T2DM (Abstract). Diabetes 52: A336, 2003.
-
(2003)
Diabetes
, vol.52
-
-
Kashyap, S.R.1
Suraamornkul, S.2
Bajaj, M.3
Belfort, R.4
Berria, R.5
Mandarino, L.6
DeFronzo, R.7
Cusi, K.8
-
36
-
-
13844262626
-
Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice
-
Kawasaki F, Matsuda M, Kanda Y, Inoue H, Kaku K. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am J Physiol Endocrinol Metab 288: E510-E518, 2005.
-
(2005)
Am J Physiol Endocrinol Metab
, vol.288
-
-
Kawasaki, F.1
Matsuda, M.2
Kanda, Y.3
Inoue, H.4
Kaku, K.5
-
37
-
-
0036310015
-
Peroxisomal proliferator-activated receptor-gamma upregulates glucokinase gene expression in beta-cells
-
Kim HI, Cha JY, Kim SY, Kim JW, Roh KJ, Seong JK, Lee NT, Choi KY, Kim KS, Ahn YH. Peroxisomal proliferator-activated receptor-gamma upregulates glucokinase gene expression in beta-cells. Diabetes 51: 676-685, 2002.
-
(2002)
Diabetes
, vol.51
, pp. 676-685
-
-
Kim, H.I.1
Cha, J.Y.2
Kim, S.Y.3
Kim, J.W.4
Roh, K.J.5
Seong, J.K.6
Lee, N.T.7
Choi, K.Y.8
Kim, K.S.9
Ahn, Y.H.10
-
38
-
-
0033864402
-
Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter
-
Kim HI, Kim JW, Kim SH, Cha JY, Kim KS, Ahn YH. Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter. Diabetes 49: 1517-1524, 2000.
-
(2000)
Diabetes
, vol.49
, pp. 1517-1524
-
-
Kim, H.I.1
Kim, J.W.2
Kim, S.H.3
Cha, J.Y.4
Kim, K.S.5
Ahn, Y.H.6
-
39
-
-
23644434430
-
Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals
-
Kim SH, Abbasi F, Chu JW, McLaughlin TL, Lamendola C, Polonsky KS, Reaven GM. Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. Diabetes 54: 2447-2452, 2005.
-
(2005)
Diabetes
, vol.54
, pp. 2447-2452
-
-
Kim, S.H.1
Abbasi, F.2
Chu, J.W.3
McLaughlin, T.L.4
Lamendola, C.5
Polonsky, K.S.6
Reaven, G.M.7
-
40
-
-
0036068327
-
Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects
-
Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, Mudaliar S, Henry RR, Kahn BB. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes 51: 443-448, 2002.
-
(2002)
Diabetes
, vol.51
, pp. 443-448
-
-
Kim, Y.B.1
Ciaraldi, T.P.2
Kong, A.3
Kim, D.4
Chu, N.5
Mohideen, P.6
Mudaliar, S.7
Henry, R.R.8
Kahn, B.B.9
-
41
-
-
15944395414
-
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program
-
Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54: 1150-1156, 2005.
-
(2005)
Diabetes
, vol.54
, pp. 1150-1156
-
-
Knowler, W.C.1
Hamman, R.F.2
Edelstein, S.L.3
Barrett-Connor, E.4
Ehrmann, D.A.5
Walker, E.A.6
Fowler, S.E.7
Nathan, D.M.8
Kahn, S.E.9
-
42
-
-
1642414416
-
Rosiglitazone prevents the impairment of human islet function induced by fatty acids: Evidence for a role of PPARγ2 in the modulation of insulin secretion
-
Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F, Marchetti P, Del Prato S. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARγ2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 286: E560-E567, 2004.
-
(2004)
Am J Physiol Endocrinol Metab
, vol.286
-
-
Lupi, R.1
Del Guerra, S.2
Marselli, L.3
Bugliani, M.4
Boggi, U.5
Mosca, F.6
Marchetti, P.7
Del Prato, S.8
-
43
-
-
0036315888
-
Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: Evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated
-
Lupi R, Dotta F, Marselli L, Del Guerra S, Masini M, Santangelo C, Patane G, Boggi U, Piro S, Anello M, Bergamini E, Mosca F, Di Mario U, Del Prato S, Marchetti P. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 51: 1437-1442, 2002.
-
(2002)
Diabetes
, vol.51
, pp. 1437-1442
-
-
Lupi, R.1
Dotta, F.2
Marselli, L.3
Del Guerra, S.4
Masini, M.5
Santangelo, C.6
Patane, G.7
Boggi, U.8
Piro, S.9
Anello, M.10
Bergamini, E.11
Mosca, F.12
Di Mario, U.13
Del Prato, S.14
Marchetti, P.15
-
44
-
-
0032005178
-
Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial
-
Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128: 176-185, 1998.
-
(1998)
Ann Intern Med
, vol.128
, pp. 176-185
-
-
Maggs, D.G.1
Buchanan, T.A.2
Burant, C.F.3
Cline, G.4
Gumbiner, B.5
Hsueh, W.A.6
Inzucchi, S.7
Kelley, D.8
Nolan, J.9
Olefsky, J.M.10
Polonsky, K.S.11
Silver, D.12
Valiquett, T.R.13
Shulman, G.I.14
-
45
-
-
0036889282
-
Meal and oral glucose tests for assessment of β-cell function: Modeling analysis in normal subjects
-
Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E. Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 283: E1159-E1166, 2002.
-
(2002)
Am J Physiol Endocrinol Metab
, vol.283
-
-
Mari, A.1
Schmitz, O.2
Gastaldelli, A.3
Oestergaard, T.4
Nyholm, B.5
Ferrannini, E.6
-
46
-
-
0036311151
-
Assessing insulin secretion by modeling in multiple-meal tests: Role of potentiation
-
Mari A, Tura A, Gastaldelli A, Ferrannini E. Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes 51, Suppl 1: S221-S226, 2002.
-
(2002)
Diabetes
, vol.51
, Issue.SUPPL. 1
-
-
Mari, A.1
Tura, A.2
Gastaldelli, A.3
Ferrannini, E.4
-
47
-
-
7044260753
-
Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma- deficient mice on a high-fat diet
-
Matsui J, Terauchi Y, Kubota N, Takamoto I, Eto K, Yamashita T, Komeda K, Yamauchi T, Kamon J, Kita S, Noda M, Kadowaki T. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma- deficient mice on a high-fat diet. Diabetes 53: 2844-2854, 2004.
-
(2004)
Diabetes
, vol.53
, pp. 2844-2854
-
-
Matsui, J.1
Terauchi, Y.2
Kubota, N.3
Takamoto, I.4
Eto, K.5
Yamashita, T.6
Komeda, K.7
Yamauchi, T.8
Kamon, J.9
Kita, S.10
Noda, M.11
Kadowaki, T.12
-
48
-
-
0036310037
-
The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes
-
Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51: 797-802, 2002.
-
(2002)
Diabetes
, vol.51
, pp. 797-802
-
-
Mayerson, A.B.1
Hundal, R.S.2
Dufour, S.3
Lebon, V.4
Befroy, D.5
Cline, G.W.6
Enocksson, S.7
Inzucchi, S.E.8
Shulman, G.I.9
Petersen, K.F.10
-
49
-
-
0035671770
-
Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients
-
Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 44: 2210-2219, 2001.
-
(2001)
Diabetologia
, vol.44
, pp. 2210-2219
-
-
Miyazaki, Y.1
Glass, L.2
Triplitt, C.3
Matsuda, M.4
Cusi, K.5
Mahankali, A.6
Mahankali, S.7
Mandarino, L.J.8
DeFronzo, R.A.9
-
50
-
-
0034833667
-
Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone
-
Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24: 710-719, 2001.
-
(2001)
Diabetes Care
, vol.24
, pp. 710-719
-
-
Miyazaki, Y.1
Mahankali, A.2
Matsuda, M.3
Glass, L.4
Mahankali, S.5
Ferrannini, E.6
Cusi, K.7
Mandarino, L.J.8
DeFronzo, R.A.9
-
51
-
-
4544325691
-
Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients
-
Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 89: 4312-4319, 2004.
-
(2004)
J Clin Endocrinol Metab
, vol.89
, pp. 4312-4319
-
-
Miyazaki, Y.1
Mahankali, A.2
Wajcberg, E.3
Bajaj, M.4
Mandarino, L.J.5
DeFronzo, R.A.6
-
52
-
-
0036517099
-
Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes
-
Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 25: 517-523, 2002.
-
(2002)
Diabetes Care
, vol.25
, pp. 517-523
-
-
Miyazaki, Y.1
Matsuda, M.2
DeFronzo, R.A.3
-
53
-
-
0035124186
-
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers
-
Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 52: 239-257, 2001.
-
(2001)
Annu Rev Med
, vol.52
, pp. 239-257
-
-
Mudaliar, S.1
Henry, R.R.2
-
54
-
-
85047693638
-
Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones
-
Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM, Kahn CR. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 112: 608-618, 2003.
-
(2003)
J Clin Invest
, vol.112
, pp. 608-618
-
-
Norris, A.W.1
Chen, L.2
Fisher, S.J.3
Szanto, I.4
Ristow, M.5
Jozsi, A.C.6
Hirshman, M.F.7
Rosen, E.D.8
Goodyear, L.J.9
Gonzalez, F.J.10
Spiegelman, B.M.11
Kahn, C.R.12
-
55
-
-
0031753344
-
Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes
-
Paolisso G, Tagliamonte MR, Rizzo MR, Gualdiero P, Saccomanno F, Gambardella A, Giugliano D, D'Onofrio F, Howard BV. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes. Diabetologia 41: 1127-1132, 1998.
-
(1998)
Diabetologia
, vol.41
, pp. 1127-1132
-
-
Paolisso, G.1
Tagliamonte, M.R.2
Rizzo, M.R.3
Gualdiero, P.4
Saccomanno, F.5
Gambardella, A.6
Giugliano, D.7
D'Onofrio, F.8
Howard, B.V.9
-
56
-
-
0024590095
-
Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance
-
Reaven GM, Hollenbeck CB, Chen YD. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia 32: 52-55, 1989.
-
(1989)
Diabetologia
, vol.32
, pp. 52-55
-
-
Reaven, G.M.1
Hollenbeck, C.B.2
Chen, Y.D.3
-
57
-
-
0141450254
-
Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis
-
Rosen ED, Kulkarni RN, Sarraf P, Ozcan U, Okada T, Hsu CH, Eisenman D, Magnuson MA, Gonzalez FJ, Kahn CR, Spiegelman BM. Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol 23: 7222-7229, 2003.
-
(2003)
Mol Cell Biol
, vol.23
, pp. 7222-7229
-
-
Rosen, E.D.1
Kulkarni, R.N.2
Sarraf, P.3
Ozcan, U.4
Okada, T.5
Hsu, C.H.6
Eisenman, D.7
Magnuson, M.A.8
Gonzalez, F.J.9
Kahn, C.R.10
Spiegelman, B.M.11
-
59
-
-
0032488968
-
Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats
-
Shimabukuro M, Zhou YT, Lee Y, Unger RH. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 273: 3547-3550, 1998.
-
(1998)
J Biol Chem
, vol.273
, pp. 3547-3550
-
-
Shimabukuro, M.1
Zhou, Y.T.2
Lee, Y.3
Unger, R.H.4
-
60
-
-
0026504160
-
Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance
-
Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41: 368-377, 1992.
-
(1992)
Diabetes
, vol.41
, pp. 368-377
-
-
Van Cauter, E.1
Mestrez, F.2
Sturis, J.3
Polonsky, K.S.4
-
61
-
-
0030977450
-
Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids
-
Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, Flier JS. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99: 2416-2422, 1997.
-
(1997)
J Clin Invest
, vol.99
, pp. 2416-2422
-
-
Vidal-Puig, A.J.1
Considine, R.V.2
Jimenez-Linan, M.3
Werman, A.4
Pories, W.J.5
Caro, J.F.6
Flier, J.S.7
-
62
-
-
0030062325
-
The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones
-
Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39: 665-668, 1996.
-
(1996)
J Med Chem
, vol.39
, pp. 665-668
-
-
Willson, T.M.1
Cobb, J.E.2
Cowan, D.J.3
Wiethe, R.W.4
Correa, I.D.5
Prakash, S.R.6
Beck, K.D.7
Moore, L.B.8
Kliewer, S.A.9
Lehmann, J.M.10
-
63
-
-
2942640242
-
Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: Impact on glucose tolerance and beta-cell function
-
Xiang AH, Peters RK, Kjos SL, Goico J, Ochoa C, Marroquin A, Tan S, Hodis HN, Azen SP, Buchanan TA. Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function. J Clin Endocrinol Metab 89: 2846-2851, 2004.
-
(2004)
J Clin Endocrinol Metab
, vol.89
, pp. 2846-2851
-
-
Xiang, A.H.1
Peters, R.K.2
Kjos, S.L.3
Goico, J.4
Ochoa, C.5
Marroquin, A.6
Tan, S.7
Hodis, H.N.8
Azen, S.P.9
Buchanan, T.A.10
-
64
-
-
33644762010
-
Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes
-
Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Kawakubo M, Buchanan TA. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 55: 517-522, 2006.
-
(2006)
Diabetes
, vol.55
, pp. 517-522
-
-
Xiang, A.H.1
Peters, R.K.2
Kjos, S.L.3
Marroquin, A.4
Goico, J.5
Ochoa, C.6
Kawakubo, M.7
Buchanan, T.A.8
-
65
-
-
19244365650
-
Thiazolidinediones
-
Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351: 1106-1118, 2004.
-
(2004)
N Engl J Med
, vol.351
, pp. 1106-1118
-
-
Yki-Jarvinen, H.1
-
66
-
-
0036789137
-
The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects
-
Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51: 2968-2974, 2002.
-
(2002)
Diabetes
, vol.51
, pp. 2968-2974
-
-
Yu, J.G.1
Javorschi, S.2
Hevener, A.L.3
Kruszynska, Y.T.4
Norman, R.A.5
Sinha, M.6
Olefsky, J.M.7
|